An R&D Year in Review-and What it Means for the Future
November 20, 2025 11:00am ETThis webinar provides a comprehensive look back at the most significant developments in R&D tax legislation and policy from the past year. One item of particular focus is on the passage of the One Big Beautiful Bill Act, which repealed the amortization requirement for domestic research expenses and reinstated immediate expensing under Section 174. We will review recent updates, highlight key financial and strategic implications, and outline best practices for maximizing credits.
Register Now to Save Your Seat
Learning Objectives
Understand the legislative changes impacting R&D treatment in 2025
Identify key IRS compliance updates effective for the current and upcoming tax years
Formulate strategic planning moves and actionable steps
Speakers
Mark McGee
Director, R&D
Mark McGee leads the R&D tax credit group at Exactera. With 18 years of R&D tax credit experience, he serves as a tax technical resource and quality assurance manager for the Exactera Professional Services Team. McGee’s expertise spans various industries, including financial services, software development, high-frequency trading, retail, pharmaceuticals, medical instruments, chemical manufacturing, integrated circuit manufacturing, automotive, agriculture, and food and beverage
Lori Towsend
Manager, R&D, Exactera
As part of Exactera’s R&D tax credit team, Lori Townsend leads client engagementsand performs in-depth reviews and analyses of financial and technical data todetermine eligible R&D expenditures. With more than 11 years of R&D tax creditexperience, she leverages her background in biomedical engineering andextensive R&D consulting to service clients. Her industries of expertise includelife science, manufacturing, software and technology, engineering, automotive, medical devices, agriculture, pharmaceutical, and food and beverage.